Company Performance Metrics
Dr. Russell Dahl: Scientific Founder, Board Member & Chief Executive Officer
Neurodon is the only company harnessing and restoring Ca2+ with first-in-class modulators. Neurodon’s compounds have undergone extensive proof-of-concept studies in animal models of diabetes, obesity, neurodegenerative disorders, and rare diseases. There are no competitors in market targeting diseases with Neurodon’s MOA and industry-leading ER
stress platform technology. We have 2 candidates in IND-enabling studies and plan to enter the clinic in 2025. Neurodon has raised >$11MM to date through a combination of state and federal grants (e.g. NIH), foundations (e.g. JDRF), partnerships, angel investments, and founder’s funds. Neurodon is currently raising a funding round to fund first in human studies for its diabetes and rare disease programs in 2025.
